The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer

Current Oncology

Volumn 16, Issue 4, 2009, Pages 25-35

  Dent, Susan ^a   Verma, Sh ^a   Latreille, J ^b   Rayson, D ^c   Clemons, M ^d   Mackey, J ^e   Verma, Su ^f   Lemieux, J ^g   Provencher, L ^g   Chia, S ^h   Wang, B ⁱ   Pritchard, K ^f  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g LAVAL UNIVERSITY   (Canada)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ Remedy Communications Limited   (Canada)

Author keywords

HER2 targeted therapy; Metastatic breast cancer; Re treatment; Trastuzumab; Treatment beyond progression

Indexed keywords

AMG 386; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEFOROLIMUS; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; EVEROLIMUS; GEMCITABINE; LAPATINIB; LETROZOLE; METHOTREXATE; NAVELBINE; PACLITAXEL; PANOBINOSTAT; PERTUZUMAB; PLACEBO; TAMOXIFEN; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG USE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MONOTHERAPY; REVIEW; SIDE EFFECT; TACHYCARDIA;

EID: 70350596106     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v16i4.469     Document Type: Review

References (67)

1. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002;62:4132-4141 (Pubitemid 34791085)
2. Quénel N, Wafflart J, Bonichon F, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995;35:283-291
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
4. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712 (Pubitemid 19147683)
5. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:1049-1056
6. Hynes NE, Stern DF. The biology of ErbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-184
7. Choi YH, Ahn JH, Kim SB, et al. Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Ann Oncol 2009;[Epub ahead of print].
8. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006;232:123-138
9. Longva KE, Pedersen NM, Haslekås C, Stang E, Madshus IH. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic downregulation of ErbB2. Int J Cancer 2005;116:359-367 (Pubitemid 40993331)
10. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739-749 (Pubitemid 38771819)
11. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002;416:279-280
12. Wen XF, Yang G, Mao W, et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006;25:6986-6996 (Pubitemid 44684839)
13. Klos KS, Zhou X, Lee S, et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003;98:1377-1385 (Pubitemid 37151491)
14. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-446 (Pubitemid 30208162)
15. Gennari R, Menard S, Fagnoni F, et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004;10:5650-5655 (Pubitemid 39180938)
16. Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006;94:259-267 (Pubitemid 43151545)
17. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 2001;61:4744-4749 (Pubitemid 32691885)
18. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792 (Pubitemid 32222155)
19. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-4274
20. Marty M, Cognetti F, Maraninchi D, et al. Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: patients surviving more than 4 years in the M77001 study [abstract 2067]. Breast Cancer Res Treat 2006;100 (suppl 1):. [Available online at: www.abstracts2view.com/sabcs06/view.php?nu= SABCS06L-1087&terms=; cited June 30, 2009]
21. Tokajuk P, Czartoryska-Arlukowicz B, Wojtukiewicz MZ, et al. Activity of trastuzumab-based therapy beyond disease progression in heavily pretreated metastatic breast cancer patients - single institution experience [abstract 13159]. Proc Am Soc Clin Oncol 2006;24:. [Available online at: www.asco. org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail-view &confID= 40&abstractID=32869; cited June 30, 2009]
22. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie 2005;28:582-586 (Pubitemid 41513144)
23. Gelmon KA, Mackey J, Verma S, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer 2004;5:52-58 (Pubitemid 38821191)
24. García-Saénz J, Martin M, Bueno C, et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer [abstract 10617]. Proc Am Soc Clin Oncol 2006;24:. [Available online at: www.asco. org/ASCOv2/Meetings/Abstracts?&vmview=abst- detail-view &confID=40&abstractID=32471; cited June 30, 2009]
25. Metro G, Mottolese M, Di Cosimo S, et al. Activity of trastuzumab (t) beyond disease progression in HER2 over-expressing metastatic breast cancer (MBC) [abstract 1066]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail-view& confID=47&abstractID=31393; cited June 30, 2009]
26. Fountzilas G, Razis E, Tsavdaridis D, et al. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer 2003;4:120-125 (Pubitemid 36939418)
27. Adamo V, Franchina T, Adamo B, et al. Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). Ann Oncol 2007;18(suppl 6):vi11-15.
28. Montemurro F, Donadio M, Clavarezza M, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006;11:318-324
29. Fabi A, Metro G, Ferretti G, et al. Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast 2008;17:499-505.
30. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063-1070 (Pubitemid 41095039)
31. Morabito A, Longo R, Gattuso D, et al. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. Oncol Rep 2006;16:393-398
32. Orlando L, Cardillo A, Ghisini R, et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. BMC Cancer 2006;6:225-233
33. Del Bianco S, Rondinelli R. Trastuzumab-containing therapies: activity beyond disease progression in M.B.C. - a pivotal experience [abstract 10788]. Proc Am Soc Clin Oncol 2006;24:. [Available online at: www.asco.org/ASCOv2/ Meetings/ Abstracts?&vmview=abst-detail-view&confID=40&abstract ID=33495; cited June 30, 2009]
34. Bartsch R, Wenzel C, Altorjai G, et al. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007;25:3853-3858 (Pubitemid 47477260)
35. Bachelot T, Mauriac L, Delcambre C, et al. Efficacy and safety of trastuzumab plus vinorelbine as second-line treatment for women with HER2-positive metastatic breast cancer beyond disease progression [abstract 1094]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCOv2/Meetings /Abstracts?&vmview=abst-detail-view&confID= 47&abstractI D=34817; cited June 30, 2009]
36. Modi S, Stopeck A, Kinden H, et al. Tanespimycin (an Hsp90 inhibitor) and trastuzumab is an active combination in patients (pts) with HER2-positive trastuzumab-refractory metastatic breast cancer (MBC): phase 2 trial [abstract 6066]. Breast Cancer Res Treat 2007;106(suppl 1):. [Available online at: www.abstracts-2view.com/sabcs07/view.php?nu=SABCS07L-1116&terms=; cited June 30, 2009]
37. Extra JM, Antoine EC, Vincent-Salomon A, Bergougnoux L, Campana F, Namer M. Favourable effect of continued trastuzumab treatment in metastatic breast cancer patients: results from the French Hermine cohort study [abstract 2064]. Breast Cancer Res Treat 2006;100(suppl 1):. [Available online at: www.abstracts-2view.com/sabcs06/view.php?nu=SABCS06L-1099&terms=; cited June 30, 2009]
38. Antoine EC, Extra JM, Vincent-Salomon A, et al. Multiple lines of trastuzumab provide a survival benefit for women with metastatic breast cancer: results from the Hermine cohort study [abstract 2099]. Eur J Cancer Suppl 2007;5:213.
39. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/ Breast International Group 03-05 study. J Clin Oncol 2009; 27:1999-2006.
40. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43. [Erratum in: N Engl J Med 2007; 356:1487]
41. Geyer CE, Martin A, Newstat B, et al. Lapatinib (l) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): genomic and updated efficacy data [abstract 1035]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ ASCOv2/Meetings/Abstracts?&vmview=abst-detail-view&c onfID=47&abstractID=35372; cited June 30, 2009]
42. O'Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract 1015]. Proc Am Soc Clin Oncol 2008;26:. [Available online at: www.asco.org/ASCOv2/ Meetings/Abstracts?&vmview=abst-detail-view&confID=55 &abstractID=36327; cited June 30, 2009]
43. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004:5:317-328 (Pubitemid 38482068)
44. Baselga J, Cameron D, Miles D, et al. Objective response rate in a phase ii multicenter trial of pertuzumab (P), a HER2 dimerization inhibiting monoclonal antibody, in combination with trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) which has progressed during treatment with T [abstract 1004]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst- detail-view&confID=47&abstractID=33765; cited June 30, 2009]
45. Fumoleau P, Wardley A, Miles D, et al. Safety of pertuzumab plus trastuzumab in a phase II trial of patients with HER2-overexpressing metastatic breast cancer which had progressed during trastuzumab therapy [abstract 73]. Breast Cancer Res Treat 2007;106(suppl 1):. [Available online at: www.abstracts-2view.com/sabcs07/view.php?nu=SABCS07L-1116&terms=; cited June 30, 2009]
46. Gelmon K, Fumoleau P, Verma S, et al. Results of a phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy [abstract 1026]. Proc Am Soc Clin Oncol 2008;26:. [Available online at: www.asco. org/ASCOv2/Meetings/Abstracts?&vmview=abst-detail-view &confID=55&abstractID=34832; cited June 30, 2009]
47. Bell R, Feng-Yi F, Barrios CH, et al. Retreatment with trastuzumab after relapse following adjuvant trastuzumab treatment (the RHEA trial): preliminary efficacy data [abstract 2120]. Eur J Cancer Suppl 2007;5:220.
48. Hoffmann-La Roche Ltd. A study of pertuzumab in combination with Herceptin (trastuzumab) and docetaxel in patients with HER2 positive metastatic breast cancer [Web protocol registry]. Protocol number WO20698 [CLEOPATRA]. Basel, Switzerland: Hoffmann-La Roche; 2008. [Available at: www.roche-trials. com/patient/trials/trial110827.html; cited: July 5, 2009]
49. Hoffmann-La Roche Ltd. A study of Avastin (bevacizumab) in combination with Herceptin (trastuzumab)/docetaxel in patients with HER2 positive metastatic breast cancer [Web protocol registry]. Protocol number BO20231 [AVEREL]. Basel, Switzerland: Hoffmann-La Roche; 2008. [Available at: www.roche-trials. com/patient/trials/trial110672.html; cited: July 5, 2009]
50. United States, National Institutes of Health, ClinicalTrials.gov. Chemotherapy and lapatinib or trastuzumab in treating women with HER2/neu-positive metastatic breast cancer [Web page]. Bethesda, MD: ClinicalTrials.gov; 2009. [Available at: clinicaltrials. gov/ct2/show/ NCT00667251; cited: April 5, 2009]
51. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab - DM1, an antibody - cytotoxic drug conjugate. Cancer Res 2008;68:9280-9290
52. Vukelja S, Rugo H, Vogel C, et al. A phase ii study of trastuzumab - DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer [abstract 33]. In: Proceedings of the 31st Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 10-14, 2008. [Available online at: www.abstracts2view.com/sabcs/view.php?nu=SABCS08L- 1329&terms=; cited June 30, 2009]
53. United States, National Institutes of Health, ClinicalTrials. gov. An open-label study of trastuzumab - MCC - DM1 (TDM-1) vs. capecitabine + lapatinib in patients with HER2-positive locally advanced or metastatic breast cancer (EMILIA) [Web page]. Bethesda, MD: ClinicalTrials.gov; 2009. [Available at: www.clinicaltrials. gov/ct2/show/NCT00829166; cited: May 6, 2009]
54. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8:249-258 (Pubitemid 32947647)
55. Noh WC, Mondesire WH, Peng J, et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004;10:1013-1023 (Pubitemid 38198903)
56. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1 - dependent pathways. Nat Med 2004;10:594-601.
57. United States, National Institutes of Health, ClinicalTrials.gov. Oral deforolimus with trastuzumab for patients with HER2-positive trastuzumab-refractory metastatic breast cancer [Web page]. Bethesda, MD: ClinicalTrials.gov; 2009. [Available at: www. clinicaltrials.gov/ct2/show/ NCT00736970; cited: May 6, 2009]
58. United States, National Institutes of Health, ClinicalTrials.gov. Everolimus in combination with trastuzumab and paclitaxel in the treatment of HER2 positive locally advanced or metastatic breast cancer (BOLERO-1) [Web page]. Bethesda, MD: ClinicalTrials. gov; 2009. [Available at: www.clinicaltrials.gov/ct2/show/NCT00876395; cited: May 6, 2009]
59. Cheung WL, Briggs SD, Allis CD. Acetylation and chromosomal functions. Curr Opin Cell Biol 2000;12:326-333
60. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000;184:1-16.
61. Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409:581-589
62. United States, National Institutes of Health, ClinicalTrials.gov. A trial of panobinostat and trastuzumab for adult female patients with HER2 positive metastatic breast cancer whose disease has progressed on or after trastuzumab [Web page]. Bethesda, MD: ClinicalTrials.gov; 2009. [Available at: www.clinicaltrials.gov/ ct2/show/NCT00567879; cited: May 6, 2009]
63. United States, National Institutes of Health, ClinicalTrials.gov. Study of panobinostat monotherapy in women with HER2 positive locally recurrent or metastatic breast cancer [Web page]. Bethesda, MD: ClinicalTrials.gov; 2009. [Available at: www.clinicaltrials. gov/ct2/show/NCT00777335; cited: May 6, 2009]
64. Perotti C, Liu R, Parusel CT, et al. Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. Breast Cancer Res 2008;10:R94.
65. United States, National Institutes of Health, ClinicalTrials.gov. Efficacy and safety study evaluating IPI-504 with trastuzumab in patients with pretreated, locally advanced or metastatic HER2 positive breast cancer [Web page]. Bethesda, MD: ClinicalTrials. gov; 2009. [Available at: www.clinicaltrials.gov/ct2/show/NCT00817362; cited: May 6, 2009]
66. Rosen LS, Hong D, Chap L, et al. First-in-human study of AMG 386, a selective angiopoietin1/2-neutralizing peptibody, in adult patients with advanced solid tumors [abstract 3522]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco. org/ASCOv2/Meetings/Abstracts?&vmview=abst- detail-view &confID=47&abstractID=32524; cited June 30, 2009]
67. United States, National Institutes of Health, ClinicalTrials.gov. Safety study of AMG 386 to treat HER2-positive locally recurrent or metastatic breast cancer [Web page]. Bethesda, MD: ClinicalTrials.gov; 2009. [Available at: www.clinicaltrials.gov/ct2/show/NCT00807859; cited: May 6, 2009]